VERICI DX PLC - Investor Presentation

Verici Dx PLC provided an investor update highlighting continued commercial progress for its AI-powered RNA diagnostics platform for kidney transplant patients, led by its flagship Tutivia post-transplant rejection test. The company reported strong operational momentum, including 32% quarter-on-quarter revenue growth, adoption across 29 US transplant centres representing approximately 20% of annual transplant activity, and nationwide regulatory approval following New York State clearance. Management reiterated its growth strategy of expanding commercial adoption through a focused US sales force, increasing recurring test volumes, strengthening clinical evidence with real-world data, and targeting high-value unmet clinical needs where its RNA technology offers advantages over traditional cell-free DNA diagnostics. Financial results showed FY2025 revenue of $3.7m, supported by Tutivia sales and milestone income from its Thermo Fisher partnership, alongside recent equity funding to extend its cash runway and support commercial expansion. The company also outlined future growth opportunities through the upcoming launch of its Protega fibrosis test, continued development of urine-based diagnostics, and expanding laboratory services. With a US addressable market estimated at $900m, a clear route towards revenue growth and operational scale, and a defined path to breakeven, Verici Dx believes it is well positioned to capitalise on increasing demand for precision transplant diagnostics and deliver long-term shareholder value.